Blood transfusions at home: a new option for terminally ill cancer patients?

NCT ID NCT05509439

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving blood transfusions at home is practical and acceptable for people with advanced blood cancers who have a life expectancy of six months or less. Ten patients were enrolled, and a trained nurse administered transfusions at home following safety guidelines. The goal was to see if patients would agree to the program, complete the transfusions, and report their experiences.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Home transfusion program (blood transfusions administered at home by a trained nurse)

What this could lead to

If successful, this could make blood transfusions more convenient and comfortable for terminally ill blood cancer patients, improving their quality of life at home.

What could go wrong

This was a very small study (10 patients) with no control group, so results may not apply to everyone. Home transfusions carry risks like allergic reactions or infections, though the program followed safety guidelines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States